- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06561958
Prospektiv, multisenter, ikke-intervensjonell studie for å undersøke effektiviteten til REKOVELLE® for eggstokkstimulering for asiatiske kvinner i virkelige omgivelser (PROFOUND)
Prospektiv, multi-lands, ikke-intervensjonell studie for å undersøke REKOVELLE for eggstokkstimulering: effektiviteten, sikkerheten og bruksmønstrene for asiatiske kvinner i praksis i den virkelige verden
Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Hiroshima, Japan, 7300035
- Ferring Investigational Site
-
Hokkaido, Japan, 0600003
- Ferring Investigational Site
-
Hyōgo, Japan, 6500021
- Ferring Investigational Site
-
Osaka, Japan, 5300011
- Ferring Investigational Site
-
Osaka, Japan, 5500015
- Ferring Investigational Site
-
Saitama, Japan, 3540035
- Ferring Investigational Site
-
-
Chiba
-
Chiba, Chiba, Japan, 2610023
- Ferring Investigational Site
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japan, 8120013
- Ferring Investigational Site
-
Kitakyushu, Fukuoka, Japan, 8070825
- Ferring Investigational Site
-
-
Gunma
-
Takasaki, Gunma, Japan, 3700841
- Ferring Investigational Site
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japan, 7320822
- Ferring Investigational Site
-
-
Japan
-
Bunkyō City, Japan, Japan, 1130033
- Ferring Investigational Site
-
-
Tokyo
-
Tokyo, Tokyo, Japan, 1600023
- Ferring Investigational Site
-
-
-
-
-
Busan, Sør -Korea, 47245
- Ferring Investigational Site
-
Seoul, Sør -Korea, 02586
- Maria Fertility Hospital
-
-
Busan
-
Busan, Busan, Sør -Korea, 49241
- Ferring Investigational Site
-
-
Daegu
-
Daegu, Daegu, Sør -Korea, 41910
- Ferring Investigational Site
-
-
Seongnam
-
Seongnam-si, Seongnam, Sør -Korea, 13496
- Ferring Investigational Site
-
-
-
-
-
Taichung, Taiwan, 406
- Ferring Investigational Site
-
Taipei, Taiwan, 100225
- Ferring Investigational Site
-
Taipei, Taiwan, 110
- Ferring Investigational Site
-
-
Tainan
-
Tainan, Tainan, Taiwan, 70403
- Ferring Investigational Site
-
Tainan, Tainan, Taiwan, 71004
- Ferring Investigational Site
-
-
Taoyuan
-
Taoyuan, Taoyuan, Taiwan, 333
- Ferring Investigational Site
-
-
-
-
-
Bangkok, Thailand, 10700
- Ferring Investigational Site
-
-
Muang
-
Phitsanulok, Muang, Thailand, 65000
- Naresuan University Hospital
-
-
Ratchathewi
-
Bangkok, Ratchathewi, Thailand, 10400
- Ramathibodi Hospital
-
-
-
-
Hanoi
-
Hanoi, Hanoi, Vietnam, 100000
- Ferring Investigational Site
-
-
Ho Chi Minh City
-
Ho Chi Minh City, Ho Chi Minh City, Vietnam, 700000
- Ferring Investigational Site
-
Ho Chi Minh City, Ho Chi Minh City, Vietnam
- Ferring Investigational Site
-
-
Huế
-
Huế, Huế, Vietnam, 49000
- Ferring Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.
Beskrivelse
Inclusion Criteria:
- Females aged 20 years or older at enrollment
- Serum AMH level >0.5 ng / mL (with the latest result tested within 12 months)
- Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
- Willing and able to provide written informed consent
Exclusion Criteria:
- Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment
- Participating in an interventional clinical trial in which any medication treatment is mandated
- Women with a contraindication for prescription of REKOVELLE treatment
- Oocyte donors
- Undergoing ovarian stimulation for fertility preservation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
REKOVELLE
Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation. |
Individualised dosing regiment of REKOVELLE in routine clinical practice. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cumulative live birth rate
Tidsramme: Up to 12 months
|
Cumulative live birth rate defined as delivery of at least 1 live fetus after 20 completed weeks of gestation, combined fresh and frozen embryo transfers within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle. |
Up to 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The Luteinising hormone (LH) surge suppression protocol
Tidsramme: Up to 22 days
|
Treatment pattern will be measured by analysing the Lutenising hormone (LH) surge suppression protocol. |
Up to 22 days
|
|
Daily Dosage
Tidsramme: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of daily dosage. |
Up to 22 days
|
|
Stimulation Duration
Tidsramme: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of stimulation duration. |
Up to 22 days
|
|
Total Dosage
Tidsramme: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of total dosage. |
Up to 22 days
|
|
Trigger Protocol
Tidsramme: Up to 22 days
|
Treatment pattern will be measured by analysing the trigger protocol. |
Up to 22 days
|
|
Luteal phase support protocol
Tidsramme: Up to 22 days
|
Treatment pattern will be measured by analysing the luteal phase support protocol. |
Up to 22 days
|
|
Number of oocytes retrieved
Tidsramme: Up to 22 days
|
Number of oocytes retrieved at oocyte retrieval |
Up to 22 days
|
|
Number of Metaphase II (MII) oocytes
Tidsramme: Up to 22 days
|
Number of MII oocytes at oocyte retrieval (only applicable for Intracytoplasmic sperm injection (ICSI)) |
Up to 22 days
|
|
Number of embryos
Tidsramme: Day 3 after oocyte retrieval
|
Number of embryos on Day 3 after oocyte retrieved |
Day 3 after oocyte retrieval
|
|
Number of Blastocysts
Tidsramme: Day 5 after oocyte retrieval
|
Number of Blastocysts on Day 5 after oocyte retrieved |
Day 5 after oocyte retrieval
|
|
Number of embryos transferred
Tidsramme: Up to 28 days
|
Embryos transferred in fresh and/or frozen transfer cycles |
Up to 28 days
|
|
Number of blastocysts transferred
Tidsramme: Up to 28 days
|
Blastocysts transferred in fresh and/or frozen transfer cycles |
Up to 28 days
|
|
Implantation rate
Tidsramme: Up to 28 days
|
Number of gestational sacs, embryos or blastocysts transferred |
Up to 28 days
|
|
Positive human chorionic gonadotropin (hCG) rate
Tidsramme: 11 to 15 days after transfer
|
Positive human chorionic gonadotropin (hCG) rate analysed using serum or urine hCG test 11-15 days after transfer |
11 to 15 days after transfer
|
|
Clinical Pregnancy rate
Tidsramme: 4 to 5 weeks after transfer
|
Clinical pregnancy rate (at least 1 gestational sac 4-5 weeks after transfer) |
4 to 5 weeks after transfer
|
|
Vital Pregnancy
Tidsramme: 4 to 5 weeks after transfer
|
Vital pregnancy rate (at least 1 intrauterine gestational sac with fetal heartbeat 4-5 weeks after transfer) |
4 to 5 weeks after transfer
|
|
Ongoing pregnancy rate
Tidsramme: 9 to 11 weeks after transfer
|
Ongoing pregnancy rate (at least 1 intrauterine viable fetus 9-11 weeks after transfer) |
9 to 11 weeks after transfer
|
|
Time to pregnancy
Tidsramme: 4 to 5 weeks after transfer
|
Time to pregnancy from start date of ovarian stimulation to confirmation of clinical pregnancy |
4 to 5 weeks after transfer
|
|
Live birth rate
Tidsramme: More than 20 weeks after transfer
|
Live birth is defined as delivery of at least 1 live fetus after 20 completed weeks of gestation within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle. |
More than 20 weeks after transfer
|
|
Multiple pregnancy rate
Tidsramme: 4 to 5 weeks after transfer
|
More than 1 gestational sac with fetal heart beat 4-5 weeks after transfer |
4 to 5 weeks after transfer
|
|
Spontaneous abortion rate
Tidsramme: Up to 10-11 weeks after transfer
|
Spontaneous abortion is defined as positive hCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound |
Up to 10-11 weeks after transfer
|
|
Ectopic pregnancy rate
Tidsramme: Up to 10-11 weeks after transfer
|
Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery. |
Up to 10-11 weeks after transfer
|
|
Estradiol Hormone levels
Tidsramme: Up to 20 days
|
Estradiol hormone levels before stimulation and at the end of stimulation day |
Up to 20 days
|
|
Progesterone Hormone levels
Tidsramme: Up to 20 days
|
Progesterone hormone levels before stimulation and at the end of stimulation day |
Up to 20 days
|
|
Cycle cancellation rate and the reason for cycle cancellation
Tidsramme: Up to 28 days
|
Date when the investigator decides to cancel cycle before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick-up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, any other specified reason) |
Up to 28 days
|
|
Transfer cancellation rate and the reason for transfer cancellation
Tidsramme: Up to 28 days
|
Transfer cancellation rate and the reason for transfer cancellation (no embryo available for transfer, risk of OHSS, endometrium not receptive, high progesterone level, adverse event, any other specified reason for transfer cancellation). |
Up to 28 days
|
|
Frequency and severity of adverse drug reactions (ADRs) and serious adverse events (SAEs)
Tidsramme: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Frequency and severity of ADRs and SAEs as defined by the investigator |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
|
Preventive interventions for ovarian hyperstimulation syndrome (OHSS)
Tidsramme: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
|
Preventive interventions decided by the investigator (Triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation, Cancellation of fresh embryo/blastocyst transfer) |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
|
|
Number of subjects with mild / moderate / severe ovarian hyperstimulation syndrome (OHSS)
Tidsramme: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Number of subjects with mild / moderate / severe OHSS, defined by the investigator |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Global Clinical Compliance, Ferring Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 000430
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .